Literature DB >> 9788017

Borderline ovarian malignancy: ultrasound and fast dynamic MR findings.

P B Van Vierzen1, L F Massuger, S H Ruys, J O Barentsz.   

Abstract

Ovarian tumors of borderline malignancy are low-grade malignant neoplasms, and have a rather good prognosis. They account for approximately 10-20% of all ovarian tumors. Very few reports available in literature that analyses ultrasound and MR findings in establishing the diagnosis. The purpose of this study is to describe eight cases of ovarian tumors of borderline malignancy with dynamic gadolinium-enhanced MR imaging. Comparison is made with CA 125 serum levels and ultrasound findings. Early enhancing endocystic vegetations, local cystic masses in, and (irregular) thickened walls of large multicystic tumors were important findings in borderline malignant tumors. The accuracy to detect a malignant tumor of borderline malignancy with CA 125, ultrasound and MRI in these eight cases was 50, 63 and 75%, respectively. MRI is a valuable imaging modality to characterize adnexal tumors and might play a role in preoperative evaluation of borderline malignancies.

Entities:  

Mesh:

Year:  1998        PMID: 9788017     DOI: 10.1016/s0720-048x(97)00122-8

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  10 in total

1.  MR imaging compared with intraoperative frozen-section examination for the diagnosis of adnexal tumors; correlation with final histology.

Authors:  Marc Bazot; Jinane Nassar-Slaba; Isabelle Thomassin-Naggara; Annie Cortez; Serge Uzan; Emile Daraï
Journal:  Eur Radiol       Date:  2006-03-18       Impact factor: 5.315

2.  Comparative evaluation of multidetector CT and MR imaging in the differentiation of adnexal masses.

Authors:  A C Tsili; C Tsampoulas; M Argyropoulou; I Navrozoglou; Y Alamanos; E Paraskevaidis; S C Efremidis
Journal:  Eur Radiol       Date:  2008-01-10       Impact factor: 5.315

3.  Use of an internal reference in semi-quantitative dynamic contrast-enhanced MRI (DCE MRI) of indeterminate adnexal masses.

Authors:  Y Z Tang; L Benardin; T C Booth; M E Miquel; P Dilks; A Sahdev; A G Rockall
Journal:  Br J Radiol       Date:  2014-09-19       Impact factor: 3.039

4.  Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study.

Authors:  Isabelle Thomassin-Naggara; Daniel Balvay; Emilie Aubert; Emile Daraï; Roman Rouzier; Charles A Cuenod; Marc Bazot
Journal:  Eur Radiol       Date:  2011-11-23       Impact factor: 5.315

5.  Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT.

Authors:  Chulhan Kim; Hyun Hoon Chung; So Won Oh; Keon Wook Kang; June-Key Chung; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2013-04-04

6.  Semi-quantitative contrast-enhanced MR analysis of indeterminate ovarian tumours: when to say malignancy?

Authors:  S M Mansour; S Saraya; Y El-Faissal
Journal:  Br J Radiol       Date:  2015-06-17       Impact factor: 3.039

7.  Can quantitative dynamic contrast-enhanced MRI independently characterize an ovarian mass?

Authors:  Philip Dilks; Priya Narayanan; Rodney Reznek; Anju Sahdev; Andrea Rockall
Journal:  Eur Radiol       Date:  2010-04-25       Impact factor: 5.315

8.  Benign and Suspicious Ovarian Masses-MR Imaging Criteria for Characterization: Pictorial Review.

Authors:  A L Valentini; B Gui; M Miccò; M C Mingote; A M De Gaetano; V Ninivaggi; L Bonomo
Journal:  J Oncol       Date:  2012-03-22       Impact factor: 4.375

9.  MRI appearance of ovarian serous borderline tumors of the micropapillary type compared to that of typical ovarian serous borderline tumors: radiologic-pathologic correlation.

Authors:  Go Nakai; Takashi Yamada; Kazuhiro Yamamoto; Yoshinobu Hirose; Masahide Ohmichi; Yoshifumi Narumi
Journal:  J Ovarian Res       Date:  2018-01-10       Impact factor: 4.234

10.  CT features of low grade serous carcinoma of the ovary.

Authors:  Harpreet K Pannu
Journal:  Eur J Radiol Open       Date:  2015-02-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.